Genfit S.A. (GNFT.PA)

EUR 3.07

(-1.98%)

Operating Expenses Summary of Genfit S.A.

  • Genfit S.A.'s latest annual operating expenses in 2023 was 54.8 Million EUR , up 33.62% from previous year.
  • Genfit S.A.'s latest quarterly operating expenses in 2024 Q2 was 29.88 Million EUR , down 0.0% from previous quarter.
  • Genfit S.A. reported a annual operating expenses of 47.49 Million EUR in annual operating expenses 2022, down -1.28% from previous year.
  • Genfit S.A. reported a annual operating expenses of 48.11 Million EUR in annual operating expenses 2021, down -38.6% from previous year.
  • Genfit S.A. reported a quarterly operating expenses of - EUR for 2023 Q3, down -100.0% from previous quarter.
  • Genfit S.A. reported a quarterly operating expenses of 63.46 Million EUR for 2023 FY, up 33.62% from previous quarter.

Annual Operating Expenses Chart of Genfit S.A. (2023 - 2005)

Created with Highcharts 11.1.0YearsOperating Expenses2006200820102012201420162018202020220 EUR25000000 EUR50000000 EUR75000000 EUR100000000 EUR

Historical Annual Operating Expenses of Genfit S.A. (2023 - 2005)

Year Operating Expenses Operating Expenses Growth
2023 54.8 Million EUR 33.62%
2022 47.49 Million EUR -1.28%
2021 48.11 Million EUR -38.6%
2020 78.35 Million EUR -11.63%
2019 88.67 Million EUR 30.97%
2018 67.7 Million EUR 24.03%
2017 54.58 Million EUR 68.18%
2016 32.45 Million EUR 99.52%
2015 16.26 Million EUR -6.93%
2014 17.47 Million EUR 58.55%
2013 11.02 Million EUR 34.53%
2012 8.19 Million EUR -5.8%
2011 8.69 Million EUR -13.39%
2010 10.04 Million EUR -6.03%
2009 10.68 Million EUR -12.36%
2008 12.19 Million EUR -9.44%
2007 13.46 Million EUR 50.99%
2006 8.91 Million EUR -8.8%
2005 9.77 Million EUR 0.0%

Peer Operating Expenses Comparison of Genfit S.A.

Name Operating Expenses Operating Expenses Difference
ABIONYX Pharma SA 4.17 Million EUR -1212.042%
ABIVAX Société Anonyme 127.37 Million EUR 56.975%
Adocia SA 15.62 Million EUR -250.656%
Aelis Farma SA 18.81 Million EUR -191.216%
Biophytis S.A. 14.33 Million EUR -282.362%
Advicenne S.A. 8.21 Million EUR -567.121%
genOway Société anonyme 16.73 Million EUR -227.417%
IntegraGen SA 5.35 Million EUR -923.893%
Medesis Pharma S.A. 1.56 Million EUR -3402.811%
Neovacs S.A. 10.34 Million EUR -429.838%
NFL Biosciences SA 4.37 Million EUR -1152.848%
Plant Advanced Technologies SA 2.76 Million EUR -1882.169%
Quantum Genomics Société Anonyme 1.71 Million EUR -3090.053%
Sensorion SA 27.05 Million EUR -102.575%
Theranexus Société Anonyme 3 Million EUR -1723.768%
TME Pharma N.V. 5.49 Million EUR -896.98%
Valbiotis SA 9.86 Million EUR -455.315%
TheraVet SA 1.64 Million EUR -3232.942%
Valerio Therapeutics Société anonyme 20.32 Million EUR -169.705%
DBV Technologies S.A. 89.4 Million EUR 38.702%
GeNeuro SA 14.35 Million EUR -281.715%
Innate Pharma S.A. 64.57 Million EUR 15.125%
Inventiva S.A. 120.18 Million EUR 54.401%
MaaT Pharma SA 21.59 Million EUR -153.746%
MedinCell S.A. 32.92 Million EUR -66.466%
Nanobiotix S.A. 58.92 Million EUR 6.997%
OSE Immunotherapeutics SA 23.58 Million EUR -132.329%
Poxel S.A. 28.76 Million EUR -90.523%
GenSight Biologics S.A. 32.66 Million EUR -67.802%
Transgene SA 31.23 Million EUR -75.479%
Valneva SE 134.92 Million EUR 59.382%